New injection for Graves' disease enters first human safety trial
NCT ID NCT07286656
First seen Dec 29, 2025 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-stage study tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to check if the drug is safe and how well people tolerate it. Researchers will monitor participants for side effects over about 5 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES' DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110801, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.